Genetic
Alpha-1 Antitrypsin Deficiency (AATD)
Understanding Alpha-1 Antitrypsin Deficiency (AATD) can be a complex journey, but with the right information and support, it's a journey you won't have to make alone.
We invite you to join our clinical trial registry, offering a unique chance to be part of AATD research. Together, we can explore potential new treatments and strategies for managing AATD, making every step forward a stride towards better health and breakthroughs in care.
Featured AATD studies enrolling now.
Enrolling Now.
The Redwood Study
The Redwood Study may help researchers better understand Alpha-1 Antitrypsin Deficiency–Associated Liver Disease and learn more about an investigational study drug.
Información
¿Quiere aprender más?
Visite la página Transparencia de Ensayos Clínicos para información más detallada sobre los ensayos clínicos de Takeda.
Regístrese Hoy.
Manténgase informado.
Al unirse a WeConnect, se le mantendrá informado de los ensayos clínicos adecuados para discutir con su proveedor de atención médica.
Alpha-1 Antitrypsin Deficiency (AATD)
Navigating life with a rare condition
Introduction to Alpha-1 Antitrypsin Deficiency (AATD)
Alpha-1 Antitrypsin Deficiency (AATD) is a genetic condition that can significantly impact lung and liver function. It results from the body not producing enough alpha-1 antitrypsin (AAT), a protein that protects the organs. Understanding AATD is crucial to help those affected and their families manage and treat this condition.
Causes and Risk Factors
AATD is caused by genetic mutations that affect the production of the AAT protein. Those with a family history of AATD or related pulmonary or liver diseases are at a heightened risk. Environmental factors, such as smoking, can worsen the effects of AATD.
Diagnosing AATD
Early and accurate diagnosis of AATD involves blood tests to measure AAT levels and genetic testing to identify specific mutations. Diagnosis is essential for initiating appropriate treatments and lifestyle adjustments to mitigate the impact on the lungs and liver.
Current Treatment Options for AATD
While there is no cure for AATD, treatment focuses on managing symptoms and preventing complications. Options include augmentation therapy to increase blood levels of AAT, medications to alleviate symptoms, and lifestyle modifications to protect lung and liver health.
Living with Alpha-1 Antitrypsin Deficiency (AATD)
Living with AATD encompasses both physical and emotional challenges. Physically, individuals may face restrictions in their daily activities due to respiratory symptoms (such as shortness of breath, chronic cough, or frequent infections like cold or flu) or liver complications (such as tiredness, loss of appetite/weight loss or yellowish discoloration of the skin), impacting their quality of life. The necessity for ongoing treatment and the potential for progressive symptoms can lead to feelings of uncertainty and anxiety about the future.
The diagnosis of a genetic condition like AATD can be overwhelming, leading to a sense of isolation and the need for support from those who understand the condition. Community, education, and advocacy can provide support to empower individuals and families to navigate the complexities of AATD.
AATD Research and Progress
Clinical research is pivotal in advancing our understanding and treatment of AATD. Takeda is committed to the development of new investigational therapies through clinical trials, focusing on the safety and effectiveness of potential treatments. Our dedication to diversity in clinical study populations helps us better understand whether new drugs under development are safe and effective for everyone affected by AATD.
Join Our Community in Pioneering Potential Health Solutions
Participation in clinical research offers hope for potentially groundbreaking treatments and a better understanding of AATD. By joining our patient registry, you will learn more about vital research that can lead to new treatment options and improved care for those with AATD.
Be Part of the Community – Sign up for our Registry Today
We invite you to join our patient registry and be informed about clinical trials for AATD. Sign up for our patient registry today. Together, we can make a difference.
How WeConnect Works.
Takeda’s patient registry for clinical trials is a breeze to sign up for.
Click the 'Register' button.
Complete a brief contact information form.
Choose your areas of interest.
Look out for a confirmation email.
And just like that—you’re all set!
Now, you can relax while we keep you updated with notifications about Takeda’s clinical trials that might be just the right fit for you.
Keep connecting.
We know you're interested in signing up for Takeda's WeConnect to get direct communication about Takeda clinical trials, but just in case you are looking for other ways to get involved – please review the information below.
Plasma donation.
Plasma-derived therapies are critical, life-saving medicines that many people with rare and complex diseases rely on. Global demand for plasma-derived products, mainly immunoglobulins, has increased dramatically in recent years.
Plasma Donation and BioLife Plasma Services
BioLife Plasma Services is Takeda’s global plasma collection network and an industry leader in the collection of high-quality plasma that is processed into life-saving plasma-based therapies that benefit thousands of people every day.
Learn more about plasma donation and how to help people who require life-saving plasma-based therapies by donating your plasma.
Physician looking to connect?
We at U.S. Medical Affairs at Takeda share your passion for science, evidence-based medicine, and commitment to promoting better health and brighter futures for our patients through potentially innovative medicines.
Our goal is to be readily available to support clinicians and researchers in whatever way we can. We believe the best way to improve disease outcomes is through robust and open communication about the science and clinical evidence.
That’s why we love to hear from medical professionals—to hear your questions, to understand what you’re seeing in the clinic, and to discuss research.
You are encouraged to report side effects or quality issues to Takeda at PVSafetyAmericas@takeda.com. If you prefer, you can report to the Health Authority.
Copyright 2024 Takeda Pharmaceutical Company Limited. All rights reserved.